Content and data provided by various third parties and Fidelity − Terms of Use

Stock Details

RELATED RESOURCES

News & Events:TENX

TENAX THERAPEUTICS INC

1.54Up 0.02 (1.3158 %)as of 4:00:00pm ET 10/27/2021

Quotes delayed at least 15 min. Log in for real time quote.

Log in for more news Show all article details.Expand all| Hide all article details.Collapse all
  1. Show article details.

    BRIEF-Tenax Therapeutics CFO Michael Jebsen To Separate From Co

    Reuters – 4:47 PM ET 10/14/2021

    Tenax Therapeutics Inc (TENX): * Tenax Therapeutics Inc (TENX) - CFO MICHAEL B. JEBSEN TO SEPARATE FROM COMPANY EFFECTIVE OCTOBER 29, 2021. * Tenax Therapeutics Inc (TENX) - CHRISTOPHER T. GIORDANO WILL ASSUME POSITION OF PRESIDENT OF COMPANY. * Tenax Therapeutics Inc (TENX) - ELIOT M. LURIER NAMED INTERIM CHIEF FINANCIAL OFFICER OF COMPANY Source text for Eikon: [https://bit.ly/3FNaqfn] Further company coverage:
  2. Show article details.

    BRIEF-Tenax Therapeutics Announces Clearance Of The Investigational New Drug Application For Imatinib In Pulmonary Arterial Hypertension

    Reuters – 8:38 AM ET 10/06/2021

    Tenax Therapeutics Inc (TENX): * TENAX THERAPEUTICS ANNOUNCES CLEARANCE OF THE INVESTIGATIONAL NEW DRUG APPLICATION FOR IMATINIB IN PULMONARY ARTERIAL HYPERTENSION. * Tenax Therapeutics Inc (TENX) - ON TRACK TO INITIATE A SINGLE PHASE 3 IN PAH IN 2Q 2022. * Tenax Therapeutics Inc (TENX) - ANTICIPATES RESULTS FROM PK STUDY IN Q4 OF 2021.
  3. Show article details.

    Tenax Therapeutics Announces Clearance of the Investigational New Drug Application for Imatinib in Pulmonary Arterial Hypertension (PAH)

    Business Wire – 8:30 AM ET 10/06/2021

    Unique, Delayed-Release Formulation of Imatinib Designed to Avoid Gastric Intolerance On Track to Initiate a Single Phase 3 in PAH in 2Q 2022 Recently Updated Company Website Highlights Imatinib Clinical Program MORRISVILLE, N.C.---- Tenax Therapeutics, Inc. (TENX), a specialty pharmaceutical company focused on identifying and developing therapeutics that address cardio-pulmonary diseases with high un...
  4. Show article details.

    Tenax Therapeutics to Present at the Benzinga Healthcare Small Cap Conference

    Business Wire – 8:30 AM ET 09/28/2021

    Tenax Therapeutics, Inc. (TENX), a specialty pharmaceutical company focused on identifying and developing therapeutics that address cardio-pulmonary diseases with high unmet medical need, today announced that management will present a company overview at the virtual Benziga Healthcare Small Cap Conference being held from September 29-30, 2021.
  5. Show article details.

    Tenax Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

    Business Wire – 8:00 AM ET 09/09/2021

    Tenax Therapeutics, Inc. (TENX), a specialty pharmaceutical company focused on identifying and developing therapeutics that address cardio-pulmonary diseases with high unmet medical need, today announced that management will present a company overview and hold virtual investor meetings at the H.C. Wainwright 23rd Annual Global Investment Conference being held September 13-15, 2021.
  6. Show article details.

    BRIEF-Tenax Therapeutics Files Prospectus Relates To Resale Of Up To 9.5 Mln Shares Of Common Stock

    Reuters – 5:14 PM ET 08/20/2021

    Tenax Therapeutics Inc (TENX): * TENAX THERAPEUTICS FILES PROSPECTUS RELATES TO RESALE OF UP TO 9.5 MILLION SHARES OF COMMON STOCK FROM TIME TO TIME BY SELLING STOCKHOLDERS Source text for Eikon: Further company coverage:
  7. Show article details.

    BRIEF-Tenax Therapeutics Inc Says On July 7, Christopher T. Giordano Was Appointed CEO, Director, Effective July 14

    Reuters – 12:22 PM ET 08/17/2021

    Tenax Therapeutics Inc (TENX). * TENAX THERAPEUTICS INC SAYS ON JULY 7, CHRISTOPHER T. GIORDANO WAS APPOINTED CEO, DIRECTOR, EFFECTIVE JULY 14 Source text for Eikon:
  8. Show article details.

    Tenax Therapeutics Reports Second Quarter 2021 Results and Provides Business Update

    Business Wire – 8:00 AM ET 08/17/2021

    Tenax Therapeutics, Inc. (TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today reported financial results for the second quarter of 2021 and provided a business update.
  9. Show article details.

    BRIEF-Tenax Announces New Publication Highlighting Novel Levosimendan Mechanism Of Action In Pulmonary Hypertension Patients With Heart Failure And Preserved Ejection Fraction (Ph-Hfpef)

    Reuters – 8:10 AM ET 08/12/2021

    Tenax Therapeutics Inc (TENX): * TENAX ANNOUNCES NEW PUBLICATION HIGHLIGHTING NOVEL LEVOSIMENDAN MECHANISM OF ACTION IN PULMONARY HYPERTENSION PATIENTS WITH HEART FAILURE AND PRESERVED EJECTION FRACTION Source text for Eikon: Further company coverage:
  10. Show article details.

    Tenax Announces New Publication Highlighting Novel Levosimendan Mechanism of Action in Pulmonary Hypertension Patients with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)

    Business Wire – 8:00 AM ET 08/12/2021

    MORRISVILLE, N.C.---- Tenax Therapeutics, Inc. (TENX), a specialty pharmaceutical company focused on identifying and developing therapeutics that address cardiopulmonary diseases with a high unmet medical need, today announced a new publication that identifies a novel mechanism of action behind the improved cardiovascular hemodynamics and exercise tolerance that was reported in the recent Phase 2 HELP...
  11. Show article details.

    Tenax Therapeutics Announced KOL Webinar on Levosimendan for Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

    Business Wire – 8:00 AM ET 08/05/2021

    Event to Focus on Current Treatment Landscape and Therapeutic Potential of Levosimendan in PH-HFpEF Monday, August 16th @ 10AM ET Tenax Therapeutics, Inc. (TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced that it will hold a KOL webinar on Levosimendan for...
Page:

Today's and Upcoming Events

  • Nov
    15

    TENX to announce Q3 earnings (Unconfirmed)

Past Events (last 90 days)

  • Aug
    17

    TENX announced Q2 earnings.

Data provided by Thomson Reuters © 2021

Technical Events

Classic Patterns (past 90 days)

PROVIDED BY RECOGNIA, INC.

View All Technical Analysis in Advanced Chart Opens in New Window

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.

Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
Copyright 1998–2021 FMR LLC. 
All rights reserved. 
Close
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.